

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/853,253	05/10/2001	Stephen R. Jaspers	00-30	5039
75	90 12/31/2002			
Robyn Adams ZymoGenetics, Inc. 1201 Eastlake Avenue East			EXAMINER PAK, YONG D	
			1652	
			DATE MAILED: 12/31/2002	9

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Comments	09/853,253	JASPERS ET AL.				
Office Action Summary	Examiner	Art Unit				
TI MANUALO DATE A Microsoft A	Yong Pak	1652				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR F THE MAILING DATE OF THIS COMMUNICAT  - Extensions of time may be available under the provisions of 37 of after SIX (6) MONTHS from the mailing date of this communicat.  - If the period for reply specified above is less than thirty (30) days.  - If NO period for reply is specified above, the maximum statutory.  - Failure to reply within the set or extended period for reply will, by.  - Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).  Status	CION.  CFR 1.136(a). In no event, however, may a licion.  s, a reply within the statutory minimum of thir period will apply and will expire SIX (6) MON y statute, cause the application to become Al	reply be timely filed ty (30) days will be considered timely. ITHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed o	n <u>25 November 2002</u> .					
2a) This action is <b>FINAL</b> . 2b)	This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims	inder Ex parte Quayle, 1900 O.	D. 11, 400 O.G. 210.				
4) Claim(s) 1,3,5,7 and 9 is/are pending in the application.						
4a) Of the above claim(s) 3,5,7 and 9 is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1</u> is/are rejected.						
7) Claim(s) is/are objected to.	7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
<ul> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>						
Attachment(s)						
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-93)</li> <li>Information Disclosure Statement(s) (PTO-1449) Paper</li> </ol>	48) 5) Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)				
I.S. Patent and Trademark Office						

Application/Control Number: 09/853,253

Art Unit: 1652

#### **DETAILED ACTION**

The amendment filed November 25, 2002, canceling claims 2, 4, 6, 8 and 10, has been entered.

Claims 1, 3, 5, 7 and 9 are pending.

#### Election/Restrictions

Applicant's election with traverse of Group I with a further election of SEQ ID NO:4 in Paper No. 7 is acknowledged. The traversal is on the ground(s) that the various polypeptides are all related because they are fragments of a longer polypeptide or that some of the polypeptides are modifications of the fragments of the longer polypeptide. SEQ ID NO:5-6 will be examined with SEQ ID NO:4, but SEQ ID NO:9 (with SEQ ID NO:10-11), SEQ ID NO:14 (with SEQ ID NO:15-16), SEQ ID NO:20 (with SEQ ID NO:21-22) and SEQ ID NO:25 (with SEQ ID NO:26) remain as patentably distinct inventions because they have different structure and have different substrate specificity.

The requirement is still deemed proper and is therefore made FINAL.

Claims 3, 5, 7 and 9 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 7.

Application/Control Number: 09/853,253

Art Unit: 1652

al.

ì

## Specification

The sequence Rules 1.821 (c) requires <u>a</u> sequence identifier for each sequences. However, the same amino acid sequence is identified by different sequence identifiers, SEQ ID NOs: 5 and 6 (see Sequence Listing, pages 3-4).

### Claim Rejections - 35 USC § 102

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by Sheppard et

Sheppard et al. (WO 98/42840) teach a polypeptide comprising SEQ ID NO:4 of the instant invention (SEQ ID NO:2, pages 55-56). Therefore, the reference of Sheppard et al. anticipates claim 1

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong Pak whose telephone number is 703-308-9363. The examiner can normally be reached on 8:00 A.M. to 4:30 P.M weekdays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 703-308-3804. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

YHTRUM: TUHOA URAHTAMOO

SUPPLEMENTAL TOTAL TEXAMINER

Yong Pak Patent Examiner December 18, 2002